AP2014007579A0 - (4-phenylimidayol-2-YL) ethylamine derivatives useful as sodium channel modulators - Google Patents

(4-phenylimidayol-2-YL) ethylamine derivatives useful as sodium channel modulators

Info

Publication number
AP2014007579A0
AP2014007579A0 AP2014007579A AP2014007579A AP2014007579A0 AP 2014007579 A0 AP2014007579 A0 AP 2014007579A0 AP 2014007579 A AP2014007579 A AP 2014007579A AP 2014007579 A AP2014007579 A AP 2014007579A AP 2014007579 A0 AP2014007579 A0 AP 2014007579A0
Authority
AP
ARIPO
Prior art keywords
phenylimidayol
sodium channel
derivatives useful
channel modulators
ethylamine derivatives
Prior art date
Application number
AP2014007579A
Other languages
English (en)
Inventor
Mark Ian Kemp
Sharanjeet Kaur Bagal
Charles Duncan Miller
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47278356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2014007579(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of AP2014007579A0 publication Critical patent/AP2014007579A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2014007579A 2011-10-26 2012-10-15 (4-phenylimidayol-2-YL) ethylamine derivatives useful as sodium channel modulators AP2014007579A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161551628P 2011-10-26 2011-10-26
PCT/IB2012/055610 WO2013061205A2 (en) 2011-10-26 2012-10-15 Chemical compounds

Publications (1)

Publication Number Publication Date
AP2014007579A0 true AP2014007579A0 (en) 2014-04-30

Family

ID=47278356

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2014007579A AP2014007579A0 (en) 2011-10-26 2012-10-15 (4-phenylimidayol-2-YL) ethylamine derivatives useful as sodium channel modulators

Country Status (28)

Country Link
US (1) US9079878B2 (xx)
EP (1) EP2771335A2 (xx)
JP (1) JP5946538B2 (xx)
KR (1) KR101586966B1 (xx)
CN (1) CN103906746B (xx)
AP (1) AP2014007579A0 (xx)
AU (1) AU2012328034B2 (xx)
BR (1) BR112014009102A2 (xx)
CA (1) CA2850925C (xx)
CL (1) CL2014000956A1 (xx)
CO (1) CO6940427A2 (xx)
CR (1) CR20140185A (xx)
CU (1) CU20140046A7 (xx)
DO (1) DOP2014000085A (xx)
EA (1) EA023375B1 (xx)
EC (1) ECSP14013324A (xx)
GT (1) GT201400079A (xx)
HK (1) HK1198650A1 (xx)
IL (1) IL232267A (xx)
MD (1) MD20140037A2 (xx)
MX (1) MX337469B (xx)
NI (1) NI201400031A (xx)
PE (1) PE20141682A1 (xx)
SG (1) SG11201401032YA (xx)
TN (1) TN2014000147A1 (xx)
UA (1) UA109220C2 (xx)
WO (1) WO2013061205A2 (xx)
ZA (1) ZA201402281B (xx)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102062323B1 (ko) * 2011-09-14 2020-01-03 다우 아그로사이언시즈 엘엘씨 보론산 및 이의 중간체 형성 방법 및 시스템
AP2016009287A0 (en) 2013-12-13 2016-06-30 Vertex Pharma Prodrugs of pyridone amides useful as modulators of sodium channels
KR102192572B1 (ko) 2014-06-09 2020-12-18 삼성전자주식회사 광원 모듈의 불량 검사방법, 광원 모듈의 제조 방법 및 광원 모듈 검사장치
WO2016065341A1 (en) * 2014-10-24 2016-04-28 Avectas Limited Delivery across cell plasma membranes
BR112017017619A2 (pt) 2015-02-19 2018-05-08 Purdue Pharma Lp métodos e composições para diminuir esvaziamento gástrico
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
CA3009715A1 (en) 2015-12-30 2017-07-06 Avectas Limited Vector-free delivery of gene editing proteins and compositions to cells and tissues
WO2018007976A1 (en) * 2016-07-06 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of pain related disorders
CA3029141A1 (en) 2016-07-06 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of pain related disorders
ES2927712T3 (es) 2017-05-16 2022-11-10 Vertex Pharma Amidas deuteradas de piridona y profármacos de las mismas como moduladores de canales de sodio
TW201920081A (zh) 2017-07-11 2019-06-01 美商維泰克斯製藥公司 作為鈉通道調節劑的羧醯胺
CA3091012A1 (en) 2018-02-12 2019-08-15 Vertex Pharmaceuticals Incorporated A method of treating pain
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US20220110923A1 (en) 2019-01-10 2022-04-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
CR20220316A (es) 2019-12-06 2022-10-07 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio
JP2024520643A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としてのヒドロキシ及び(ハロ)アルコキシ置換テトラヒドロフラン
AU2022286438A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
CN117813302A (zh) 2021-06-04 2024-04-02 沃泰克斯药物股份有限公司 经取代的四氢呋喃-2-甲酰胺作为钠通道调节剂
BR112023025264A2 (pt) 2021-06-04 2024-02-20 Vertex Pharma Formas farmacêuticas sólidas e regimes posológicos compreendendo (2r,3s,4s,5r)-4-[[3- (3,4-difluoro-2-metóxi-fenil)-4,5-dimetil-5-(trifluorometil) tetra-hidrofuran-2-carbonil]amino ]piridina-2-carboxamida
AU2022285758A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
CN117794920A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂
US20230373925A1 (en) 2022-04-22 2023-11-23 Vertex Pharma Heteroaryl compounds for the treatment of pain
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
US20230382910A1 (en) 2022-04-22 2023-11-30 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205465A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023211990A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
WO2024123815A1 (en) 2022-12-06 2024-06-13 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US7291641B2 (en) * 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
US7112366B2 (en) 2001-01-05 2006-09-26 The Ohio State University Chemical monolayer and micro-electronic junctions and devices containing same
TWI248438B (en) * 2001-04-10 2006-02-01 Sod Conseils Rech Applic Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
FR2842808B1 (fr) * 2002-07-25 2004-09-10 Sod Conseils Rech Applic Nouveaux derives d'arylimidazoles, leur preparation et leurs applications therapeutiques
US7456164B2 (en) * 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
DE602005022062D1 (de) * 2004-05-07 2010-08-12 Warner Lambert Co Als h3-liganden geeignete 3- oder 4-monosubstituierte phenol- und thiophenol-derivate
AU2005299310A1 (en) * 2004-10-27 2006-05-04 Canji, Inc. Compositions and methods for short interfering nucleic acid inhibition of Nav1.8
EP1963280B1 (en) * 2005-12-22 2015-10-28 Newron Pharmaceuticals S.p.A. 2-phenylethylamino derivatives as calcium and/or sodium channel modulators
PT2076508E (pt) 2006-10-18 2011-03-07 Pfizer Prod Inc Compostos de ureia de éter biarílico
US8357711B2 (en) 2007-03-23 2013-01-22 Pfizer Limited Heterocyclic sulfonamides as inhibitors of ion channels
EP2155727A1 (en) * 2007-05-03 2010-02-24 Pfizer Limited N-[6-amino-5-(phenyl)pyrazin-2-yl]-isoxazole-4-carboxamide derivatives and related compounds as nav1.8 channel modulators for the treatment of pain
KR20100007956A (ko) 2007-05-03 2010-01-22 화이자 리미티드 나트륨 채널 조절제로서의 2-피리딘 카복스아마이드 유도체
EP2173743A2 (en) 2007-07-13 2010-04-14 Icagen, Inc. Sodium channel inhibitors

Also Published As

Publication number Publication date
CN103906746A (zh) 2014-07-02
EA023375B1 (ru) 2016-05-31
CU20140046A7 (es) 2014-10-02
CL2014000956A1 (es) 2014-07-18
CN103906746B (zh) 2015-12-09
MD20140037A2 (ro) 2014-08-31
PE20141682A1 (es) 2014-11-14
AU2012328034B2 (en) 2015-04-23
CA2850925A1 (en) 2013-05-02
MX2014004738A (es) 2014-08-01
EA201490864A1 (ru) 2014-08-29
EP2771335A2 (en) 2014-09-03
DOP2014000085A (es) 2014-08-31
BR112014009102A2 (pt) 2017-04-18
AU2012328034A1 (en) 2014-05-15
ZA201402281B (en) 2015-11-25
JP2014530900A (ja) 2014-11-20
IL232267A (en) 2016-10-31
US20140296313A1 (en) 2014-10-02
WO2013061205A8 (en) 2014-03-27
KR101586966B1 (ko) 2016-01-19
NZ623090A (en) 2015-10-30
KR20140069234A (ko) 2014-06-09
NI201400031A (es) 2014-10-01
MX337469B (es) 2016-03-02
CR20140185A (es) 2014-06-03
US9079878B2 (en) 2015-07-14
ECSP14013324A (es) 2014-05-31
IL232267A0 (en) 2014-06-30
CO6940427A2 (es) 2014-05-09
HK1198650A1 (en) 2015-05-22
WO2013061205A2 (en) 2013-05-02
CA2850925C (en) 2017-01-10
TN2014000147A1 (fr) 2015-09-30
JP5946538B2 (ja) 2016-07-06
GT201400079A (es) 2015-06-02
WO2013061205A3 (en) 2013-06-27
SG11201401032YA (en) 2014-07-30
UA109220C2 (uk) 2015-07-27

Similar Documents

Publication Publication Date Title
HK1198650A1 (en) (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators (4--2-)
HK1238627A1 (zh) 作為離子通道調節劑的稠合雜環化合物
HK1200713A1 (en) Benzyl sulfonamide derivatives as rorc modulators rorc
PL2581991T3 (pl) Rama nośna dla łączników wtykowych
HK1201526A1 (zh) 作為 調節劑的苄基磺酰胺衍生物
PT2663550T (pt) Benzoazepinas substítuidas utilizáveis como moduladores dos recetores tipo toll
EP2663555A4 (en) SUBSTITUTED BENZOAZEPINES AS GREAT LIKE RECEPTOR MODULATORS
EP2794880A4 (en) METHODS FOR MODULATING EXPRESSION OF METASTASIS-ASSOCIATED ADENOCARCINOMA TRANSCRIPT (MALAT-1)
EP2709985A4 (en) AMINE DERIVATIVES AS BLOCKERS OF THE POTASSIUM CHANNEL
EP2568021B8 (en) Ink Composition
EP2661179A4 (en) COMPOSITION WITH REDUCED SODIUM CONTENT
EP2659313A4 (en) Printing
EP2676553A4 (en) COMPOSITION CONTAINING CAROTENOIDS
HK1190884A1 (en) Carotenoid coloring composition
HK1179956A1 (zh) 作為 調節劑的稠合雜環衍生物
IL233001A0 (en) New iso-ergoline histories
EP2688426A4 (en) SALT COMPOSITION WITH REDUCED SODIUM CONTENT
HK1196605A1 (zh) -氧代-哌啶基衍生物
AU2012902375A0 (en) Low sodium salt
AU2011903092A0 (en) Improvements Relating To Printing
GB201106990D0 (en) Connector for frames
GB201101084D0 (en) Connector for frames
GB201220680D0 (en) Antibacterials
AU2011903834A0 (en) Alignment Apparatus
AU2011903178A0 (en) 888-SuperPower (KineticEnergy2ElectricPower)